Bevacizumab-IRDye800 as an imaging probe for the detection of prostate cancer in mice

Read full text Summarise with VIRAT
Authors: Coralie Genevois, Nathalie Dugot‐Senant, Marie‐Hélène Canron, Lamia Azzi Martin, N. Grenier, Franck Couillaud, Claire Mazzocco
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Vascular endothelial growth factor (VEGF) signalling plays a critical role in carcinogenesis and tumour development in several types of cancer. Therefore, we sought to evaluate a fluorescently labelled monoclonal antibody against VEGF-A (Bevacizumab) as a probe for the detection of prostate cancer by in vivo fluorescence imaging. An orthotopic model of prostate cancer was generated by injecting bioluminescent human PC3 cells into the prostate lobe, followed by bioluminescence in vivo. Bevacizumab was labelled using a near-infrared fluorophore to generate a specific imaging probe (Bevacizumab-IRDye800). The probe was injected intravenously into prostate cancer-bearing mice, and fluorescence was monitored in vivo by fluorescence molecular tomography (FMT). 72 h post-injection, Bevacizumab-IRDye800 was detected in vivo by FMT in the prostate region. On excised prostates, the fluorescence signal overlaid with the bioluminescent signal from cancer cells. Our data demonstrate that Bevacizumab-IRDye800 is a high-affinity contrast agent for in vivo detection of prostate cancer tumours, paving the way to further development of near-infrared-labelled Bevacizumab-IRDye800 for the detection of other solid cancers.

Fields of Study & Subjects

Optical Imaging and Spectroscopy Techniques Nanoplatforms for cancer theranostics Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Scientific Reports
Volume
16
Issue
1
Publication date
26 March 2026
Language
EN